Anderman Todd
Chief Legal Officer
Anderman Todd has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Oct 13, 2026.
On the most recent filing, Anderman Todd is listed as Chief Legal Officer at OCULAR THERAPEUTIX, INC. Inside the rolling window, Anderman Todd reported no open-market purchases and 1 open-market sale totaling $87K in OCUL.
Companies traded
Other insiders at OCUL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$87K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Oct 8, 2025 | OCUL | Sale | $137K |
Frequently asked questions
How many SEC Form 4 filings has Anderman Todd made?
Anderman Todd has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2025.
Which companies does Anderman Todd trade?
Anderman Todd has filed SEC Form 4 disclosures for 1 company, including OCUL.
When was Anderman Todd's most recent SEC Form 4 filing?
Anderman Todd's most recent SEC Form 4 filing on Tracefour is dated Oct 13, 2026.
What is Anderman Todd's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Anderman Todd is listed as Chief Legal Officer.
What is Anderman Todd's total buy and sell value in the current window?
Inside the rolling retention window, Anderman Todd bought $0 and sold $87K based on SEC Form 4 filings.
What was Anderman Todd's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 11,984 OCUL shares on 2026-10-08, worth $87K, per SEC Form 4 filings.